why choose us

First received: August 9, 2022

Clinical Trial: Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019

Study Status: Completed

Recruit Status: Completed

Condition: Coronavirus Disease 2019

Study Type: Interventional


Official Title: Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019: a Single-center, Open-label, Parallel-group Randomized Controlled Clinical Trial

Brief Summary: The investigators conducted a single-center, open-label, parallel-group randomized controlled trial to assess the efficacy and safety of a Chinese herb compound granule Huashi Baidu granule (HSBDG) in pediatric patients with laboratory-confirmed mild COVID-19. 108 recruited children (aged 3 to 18 years) with laboratory-confirmed mild COVID-19 were randomly allocated 2:1 to receive oral HSBDG for 5 consecutive days (intervention group) and to receive compound pholcodine oral solution for 5 consecutive days (control…

Read more